Raul Zavaleta has over 30 years of international experience in life sciences. In 1986, he moved from Los Angeles, California, to start his first venture in Indianapolis, Indiana. This venture, SciCor, now Covance, Inc. (NYSE:CVD), quickly became the leader in the pharmaceutical industry for laboratory services. In 1991, after SciCor was acquired by Corning, Inc., Zavaleta moved to Geneva, Switzerland, where he led the expansion of SciCor to Western and Eastern Europe. Using the same process pioneered in the United States, the enterprise successfully conquered the transportation logistics challenge that Europe presented and quickly became the standard for the industry.
Upon his return from Geneva in late 1993, Zavaleta continued his entrepreneurial career starting or mentoring several technology companies, including the following:
Avantec, a pioneering company in Electronic Data Collection (EDC) whose innovation led to widespread adoption of EDC in pharmaceutical clinical trials;
Performance Assessment Network (PAN), the leading web-based system for the distribution, administration, and analysis of professional assessments, tests, and surveys, which he helped found and grow to to a succesfull exit on an acquisition by Talx , itself acquired by Equifax (NYSE:EFX);
Strategies For Tomorrow, one of the leading national consulting firms advising communities in the formation and implementation of community based Health Information Exchanges (HIEs) – also known as Regional Health Information Organizations (RHIOs) – to serve as conduits for the exchange of medical records by hospitals, physicians, clinics, diagnostic laboratories, public health and patients. Strategies For Tomorrow has been the leading advisor in more than 20 community HIE initiatives in 10 states;
Strand Analytical Laboratories, a premier national private laboratory for outsourced DNA testing for forensic applications. As such, Strand Analytical Laboratories partners with public crime labs to reduce casework backlogs, solve more crimes, and protect the public from repeat offenders. The company developed the know error® system, which added DNA matching to the diagnostic testing cycle of patients’ biopsy tissue samples to ensure specimen identity and diagnostic accuracy;
Maaguzi, a leading provider of software, services, and the power of the Internet for the electronic collection of patient reported outcomes in late phase clinical research conducted by pharmaceutical and biotechnology companies with its powerful suite of product offerings (OutcomeLogix and SleepLogix). After being an advisor consultant, Zavaleta was named CEO and positioned and grew the company leading to its acquisition by Phase Forward (NASDAQ:PFWD) within 18 months of his appointment. Phase Forward has since been acquired by Oracle (Nasdaq: ORCL);
Indigo BioSystems. With its industry leading software, ASCENT, Indigo uses advanced algorithms to automatically analyze and report correct data, and flagging only the outliers for expert review. ASCENT delivers an outstanding Return-On-Investment to clinical and toxicology laboratories, while improving the quality and reducing test turn-around-time. He just completed a stint as CEO of Indigo BioSystems, Inc., a provider of scientific software automation solutions for expert processes in analytical laboratories. Zavaleta transformed the company from a perpetual license business model to a Software-As-A-Service model for its flagship product ASCENT, which has become an industry leading product;
Prior to beginning his entrepreneurial career, Zavaleta worked for Dow Chemical, American Hospital Supply, and Smith Kline Beecham Laboratories. He has a Bachelor of Science degree in Chemical Engineering degree from the University of California at Los Angeles (UCLA).